Early-phase clinical studies also investigated the effect of quizartinib in association with chemotherapy with encouraging results [64]; therefore, a phase III trial that compared the efficacy of quizartinib versus placebo, both administered with standard induction and consolidation chemotherapy, in AML patients with FLT3/ITD mutations, is still recruiting participants (NCT02668653). The gene discussed is FLT3; the disease is acute myeloid leukemia.